These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35528961)

  • 1. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020.
    Munywoki PK; Nasimiyu C; Alando MD; Otieno N; Ombok C; Njoroge R; Kikwai G; Odhiambo D; Osita MP; Ouma A; Odour C; Juma B; Ochieng CA; Mutisya I; Ngere I; Dawa J; Osoro E; Njenga MK; Bigogo G; Munyua P; Lo TQ; Hunsperger E; Herman-Roloff A
    F1000Res; 2021; 10():853. PubMed ID: 35528961
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021.
    Munywoki PK; Bigogo G; Nasimiyu C; Ouma A; Aol G; Oduor CO; Rono S; Auko J; Agogo GO; Njoroge R; Oketch D; Odhiambo D; Odeyo VW; Kikwai G; Onyango C; Juma B; Hunsperger E; Lidechi S; Ochieng CA; Lo TQ; Munyua P; Herman-Roloff A
    Gates Open Res; 2023; 7():101. PubMed ID: 37990692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
    Kagucia EW; Ziraba AK; Nyagwange J; Kutima B; Kimani M; Akech D; Ng'oda M; Sigilai A; Mugo D; Karanja H; Gitonga J; Karani A; Toroitich M; Karia B; Otiende M; Njeri A; Aman R; Amoth P; Mwangangi M; Kasera K; Ng'ang'a W; Voller S; Ochola-Oyier LI; Bottomley C; Nyaguara A; Munywoki PK; Bigogo G; Maitha E; Uyoga S; Gallagher KE; Etyang AO; Barasa E; Mwangangi J; Bejon P; Adetifa IMO; Warimwe GM; Scott JAG; Agweyu A
    Influenza Other Respir Viruses; 2023 Sep; 17(9):e13173. PubMed ID: 37752065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya.
    Ngere I; Dawa J; Hunsperger E; Otieno N; Masika M; Amoth P; Makayotto L; Nasimiyu C; Gunn BM; Nyawanda B; Oluga O; Ngunu C; Mirieri H; Gachohi J; Marwanga D; Munywoki PK; Odhiambo D; Alando MD; Breiman RF; Anzala O; Njenga MK; Bulterys M; Herman-Roloff A; Osoro E
    Int J Infect Dis; 2021 Nov; 112():25-34. PubMed ID: 34481966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of anti-SARS-CoV-2 antibodies among children and their parents in Greece.
    Dimopoulou D; Kyritsi M; Dadouli K; Vergadi E; Tsiligianni E; Papadimitriou E; Mavridi A; Giannakopoulos S; Tsiourvopoulou G; Palyvou M; Angeli E; Brikos N; Eleftheriou I; Spoulou V; Michos A; Gkentzi D; Siomou E; Papaevangelou V; Grivea I; Syrogiannopoulos G; Galanakis E; Hadjichristodoulou C; Tsolia M
    Eur J Pediatr; 2023 Jan; 182(1):439-449. PubMed ID: 36383284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
    Etyang AO; Lucinde R; Karanja H; Kalu C; Mugo D; Nyagwange J; Gitonga J; Tuju J; Wanjiku P; Karani A; Mutua S; Maroko H; Nzomo E; Maitha E; Kamuri E; Kaugiria T; Weru J; Ochola LB; Kilimo N; Charo S; Emukule N; Moracha W; Mukabi D; Okuku R; Ogutu M; Angujo B; Otiende M; Bottomley C; Otieno E; Ndwiga L; Nyaguara A; Voller S; Agoti CN; Nokes DJ; Ochola-Oyier LI; Aman R; Amoth P; Mwangangi M; Kasera K; Ng'ang'a W; Adetifa IMO; Wangeci Kagucia E; Gallagher K; Uyoga S; Tsofa B; Barasa E; Bejon P; Scott JAG; Agweyu A; Warimwe GM
    Clin Infect Dis; 2022 Jan; 74(2):288-293. PubMed ID: 33893491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.
    Murhekar MV; Bhatnagar T; Selvaraju S; Rade K; Saravanakumar V; Vivian Thangaraj JW; Kumar MS; Shah N; Sabarinathan R; Turuk A; Anand PK; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chakraborty D; Rangaraju C; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Salim Khan SM; Haq I; Kumar MS; Laxmaiah A; Madhuka ; Mahapatra A; Mitra A; Nirmala AR; Pagdhune A; Qurieshi MA; Ramarao T; Sahay S; Sharma YK; Shrinivasa MB; Shukla VK; Singh PK; Viramgami A; Wilson VC; Yadav R; Girish Kumar CP; Luke HE; Ranganathan UD; Babu S; Sekar K; Yadav PD; Sapkal GN; Das A; Das P; Dutta S; Hemalatha R; Kumar A; Narain K; Narasimhaiah S; Panda S; Pati S; Patil S; Sarkar K; Singh S; Kant R; Tripathy S; Toteja GS; Babu GR; Kant S; Muliyil JP; Pandey RM; Sarkar S; Singh SK; Zodpey S; Gangakhedkar RR; S Reddy DC; Bhargava B
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):48-60. PubMed ID: 32952144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.
    Raqib R; Sarker P; Akhtar E; Nurul Huda TM; Haq MA; Roy AK; Hosen MB; Haque F; Chowdhury MR; Reidpath DD; Emdadul Hoque DM; Islam Z; Ahmed S; Ahmed T; Tofail F; Razzaque A
    PLoS One; 2022; 17(5):e0268093. PubMed ID: 35604947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey.
    Fofana MO; Nery N; Aguilar Ticona JP; de Andrade Belitardo EMM; Victoriano R; Anjos RO; Portilho MM; de Santana MC; Dos Santos LL; de Oliveira D; Cruz JS; Muenker MC; Khouri R; Wunder EA; Hitchings MDT; Johnson O; Reis MG; Ribeiro GS; Cummings DAT; Costa F; Ko AI
    PLoS Med; 2022 Sep; 19(9):e1004093. PubMed ID: 36074784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
    Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
    Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in SARS-CoV-2 Infection by Race, Ethnicity, Language, and Social Vulnerability: Evidence from a Citywide Seroprevalence Study in Massachusetts, USA.
    Matias WR; Fulcher IR; Sauer SM; Nolan CP; Guillaume Y; Zhu J; Molano FJ; Uceta E; Collins S; Slater DM; Sánchez VM; Moheed S; Harris JB; Charles RC; Paxton RM; Gonsalves SF; Franke MF; Ivers LC
    J Racial Ethn Health Disparities; 2024 Feb; 11(1):110-120. PubMed ID: 36652163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among unvaccinated children of Chandigarh, Northwest India, in a household-based paediatric serosurvey post-second wave of pandemic (June to July 2021).
    Ghosh A; Goyal K; Singh R; Lakshmi PVM; Kaur R; Kumar V; Muralidharan J; Puri GD; Ram J; Singh MP
    Public Health; 2023 Dec; 225():160-167. PubMed ID: 37931485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark.
    Fogh K; Eriksen ARR; Hasselbalch RB; Kristensen ES; Bundgaard H; Nielsen SD; Jørgensen CS; Scharff BFSS; Erikstrup C; Sækmose SG; Holm DK; Aagaard B; Norsk J; Nielsen PB; Kristensen JH; Østergaard L; Ellermann-Eriksen S; Andersen B; Nielsen H; Johansen IS; Wiese L; Simonsen L; Fischer TK; Folke F; Lippert F; Ostrowski SR; Ethelberg S; Koch A; Vangsted AM; Krause TG; Fomsgaard A; Nielsen C; Ullum H; Skov R; Iversen K
    BMC Infect Dis; 2022 Feb; 22(1):143. PubMed ID: 35144550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
    Chervo TC; Elkin EP; Nugent JR; Valice E; Amsden LB; Ergas IJ; Munneke JR; Flores M; Saelee GN; Hsiao CA; Schapiro JM; Quesenberry CP; Corley DA; Habel LA; Kushi LH; Skarbinski J
    PLoS One; 2024; 19(6):e0303303. PubMed ID: 38900738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya.
    Awandu SS; Ochieng Ochieng A; Onyango B; Magwanga RO; Were P; Atieno Ochung' A; Okumu F; Oloo MA; Katieno JS; Lidechi S; Ogutu F; Awuor D; Kirungu JN; Orata F; Achieng J; Oure B; Nyunja R; Muok EMO; Munga S; Estambale B
    PLoS One; 2022; 17(12):e0272751. PubMed ID: 36548358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
    Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
    Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.
    Fish CS; Owiti P; Begnel ER; Itell HL; Ojee E; Adhiambo J; Ogweno V; Holland LA; Richardson BA; Khan AK; Maqsood R; Gantt S; Lim ES; Slyker J; Kinuthia J; Overbaugh J; Wamalwa D; Lehman DA; Chohan BH
    J Med Virol; 2023 Jan; 95(1):e28221. PubMed ID: 36251533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.